ANRO

In March 2026, Alto Neuroscience announced a $120 million private placement financing and reported its full-year 2025 financial results. In April 2026, the company reported topline data from its Phase 2 proof-of-concept study of ALTO-101 and initiated a Phase 2b trial of ALTO-207 in treatment-resistant depression. In May 2026, the company presented Phase 2a data for ALTO-207 in Major Depressive Disorder at the SOBP Annual Meeting. The company's stock price has seen significant movement, increasing from $2.35 per share on May 5, 2025, to $25.225 on May 5, 2026, and increasing by 36.1% from the beginning of 2026 to $24.2590 by May 9, 2026.